Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more

Recent & Breaking News (NDAQ:CTMX)

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

GlobeNewswire November 7, 2022

CytomX Therapeutics to Present at Upcoming November Investor Conferences

GlobeNewswire November 2, 2022

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

GlobeNewswire November 1, 2022

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

GlobeNewswire September 12, 2022

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

GlobeNewswire September 7, 2022

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 4, 2022

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

GlobeNewswire August 3, 2022

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 28, 2022

CytomX Therapeutics Provides Strategic Update

GlobeNewswire July 13, 2022

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

GlobeNewswire July 6, 2022

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire June 16, 2022

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

GlobeNewswire June 1, 2022

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

GlobeNewswire May 26, 2022

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 5, 2022

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

GlobeNewswire April 28, 2022

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

GlobeNewswire April 14, 2022

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

GlobeNewswire March 23, 2022

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

GlobeNewswire March 17, 2022

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

GlobeNewswire March 1, 2022

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

GlobeNewswire February 28, 2022